Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").
Sign Up to like & getrecommendations! Published in 2019 at "Translational andrology and urology"
DOI: 10.21037/tau.2019.09.19
Abstract: The publication in 2017 of the KEYNOTE 045 prospective randomized phase 3 trial comparing pembrolizumab anti PD1 antibody with conventional cytotoxic chemotherapy in treatment of recurrent urothelial cancer (1) marked a watershed for immune treatment… read more here.
Keywords: keynote 045; urothelial cancer; commentary year; year follow ... See more keywords
Commentary: 20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Psychiatry"
DOI: 10.3389/fpsyt.2020.592593
Abstract: Université de Paris – INSERM UMRS 1144, Paris, France, 2 Assistance Publique des Hôpitaux de Paris, APHP.Nord, DMU Neurosciences, GHU Saint Louis-Lariboisière-Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France, 3 Fondation Fondamental,… read more here.
Keywords: trends pharmacologic; pharmacologic treatment; commentary year; year trends ... See more keywords